Holen Sie sich die Stockscreener-App
42.11
5.54%
-2.2273
Schlusskurs vom Vortag:
$44.34
Offen:
$43.44
24-Stunden-Volumen:
830.46K
Relative Volume:
0.69
Marktkapitalisierung:
$1.69B
Einnahmen:
$147.17M
Nettoeinkommen (Verlust:
$-408.35M
KGV:
-3.7672
EPS:
-11.1787
Netto-Cashflow:
$-299.01M
1W Leistung:
-16.61%
1M Leistung:
-57.04%
6M Leistung:
+10.11%
1J Leistung:
+55.59%
1-Tages-Spanne:
$41.53
$44.95
1-Wochen-Bereich:
$41.53
$51.15
52-Wochen-Spanne:
$20.44
$118.84
Grail Inc Stock (GRAL) Company Profile
Firmenname
Grail Inc
Sektor
Branche
Telefon
(833) 694-2553
Adresse
1525 O'BRIEN DRIVE, MENLO PARK
Compare GRAL vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GRAL
Grail Inc
|
41.97 | 1.79B | 147.17M | -408.35M | -299.01M | -11.18 |
|
TMO
Thermo Fisher Scientific Inc
|
469.51 | 176.79B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
186.29 | 131.71B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
569.85 | 45.48B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
111.56 | 31.55B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
284.74 | 27.79B | 3.17B | 642.63M | 516.49M | 10.77 |
Grail Inc Stock (GRAL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-19 | Eingeleitet | TD Cowen | Hold |
| 2026-02-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-11-12 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-04-21 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-11-27 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-10-17 | Eingeleitet | Guggenheim | Neutral |
Alle ansehen
Grail Inc Aktie (GRAL) Neueste Nachrichten
Assessing GRAIL (GRAL) Valuation After Recent Share Price Volatility and Narrative Fair Value Gap - simplywall.st
Grail Inc. Announces CEO Transition - Contract Pharma
Grail CEO to retire after failed cancer detection trial - The Business Journals
(GRAL) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Freidin, Grail CFO, sells $154k in GRAL stock - Investing.com Nigeria
Grail CEO Bob Ragusa retiring, Josh Ofman appointed successor - TipRanks
GRAIL, Inc. 2025 Annual Report: Multi-Cancer Early Detection with Galleri, Company Strategy, and Key Business Risks - Minichart
GRAIL, Inc. Announces Chief Executive Officer Changes, Effective June 1, 2026 - marketscreener.com
GRAIL names Josh Ofman as CEO, Bob Ragusa to retire June 1 - Investing.com
Cancer detection company GRAIL elevates Josh Ofman to lead multi-cancer efforts - Stock Titan
Levi & Korsinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed - GlobeNewswire
GRAIL, Inc. Hits Day High with 12.18% Surge Amid Market Challenges - Markets Mojo
Here's Why Grail Shares Crashed in February and Why it Could Be a Buying Opportunity - AOL.com
Grail Inc’s Earnings Call Balances Momentum and Risk - TipRanks
A Persistent Patient’s Story - RealClearHealth
Aaron Freidin Sells 2,492 Shares of GRAIL (NASDAQ:GRAL) Stock - MarketBeat
Joshua Ofman Sells 2,937 Shares of GRAIL (NASDAQ:GRAL) Stock - MarketBeat
Insider Selling: GRAIL (NASDAQ:GRAL) CEO Sells 7,461 Shares of Stock - MarketBeat
Freidin, Grail CFO, sells $154k in GRAL stock By Investing.com - Investing.com Australia
Ofman Joshua J. (GRAIL) sells $177k in shares - Investing.com South Africa
Grail CEO Ragusa sells $409k in shares - Investing.com
Samsung and GRAIL Announce Strategic Collaboration To Bring GRAIL’s Galleri® Multi-Cancer Early Detection Test to Asia - Samsung Global Newsroom
GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.” Mainstream epidemiologists beg to differ - The Cancer Letter
GRAIL, Inc. $GRAL Shares Purchased by JPMorgan Chase & Co. - MarketBeat
How Investors Are Reacting To GRAIL (GRAL) Mixed NHS-Galleri Trial Results And Ongoing Net Losses - Sahm
POM Health Announces Agreement with GRAIL to Offer Its Galleri® MCED Test - PR.com
Here's Why Grail Stock Bounced Back 16% Today - AOL.com
Levi & Korskinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed - GlobeNewswire
Vanguard Group Inc. Trims Stock Position in GRAIL, Inc. $GRAL - MarketBeat
Crcm LP Has $108.96 Million Holdings in GRAIL, Inc. $GRAL - MarketBeat
GRAIL, Inc. Hits Day Low of $41.50 Amid Price Pressure - Markets Mojo
GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES - Seeking Alpha
Grail Insider Sold Shares Worth $1,881,417, According to a Recent SEC Filing - marketscreener.com
GRAIL (NASDAQ:GRAL) CFO Aaron Freidin Sells 9,573 Shares - MarketBeat
Insider Selling: GRAIL (NASDAQ:GRAL) CEO Sells 37,504 Shares of Stock - MarketBeat
GRAL | GRAIL, Inc. Common Stock FinancialsIncome Statement - Quiver Quantitative
GRAIL (GRAL) president gets RSU grant, sells shares for taxes - Stock Titan
GRAIL (GRAL) CFO awarded 60,118 RSUs, sells shares to cover taxes - Stock Titan
GRAIL (GRAL) CEO sells 37,504 shares in automatic tax sell-to-cover - Stock Titan
GRAIL, Inc. (GRAL) Stock Analysis: Investor Outlook On A 67.21% Potential Upside - DirectorsTalk Interviews
GRAL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
GRAIL, Inc. Hits Day Low of $52.56 Amid Price Pressure - Markets Mojo
GRAL: NHS-Galleri trial showed strong stage 4 cancer reduction and broad commercial momentum - TradingView
GRAIL (GRAL) Valuation Check As NHS Galleri Trial Data And Earnings Reset Growth Expectations - simplywall.st
GRAL: Affiliate to sell 36,923 vested RSU shares (Form 144) - Stock Titan
GRAL (NASDAQ) insider sale: Robert Ragusa sells 40,000 shares; 74,873 RSUs vested - Stock Titan
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - ChartMill
GRAIL (NASDAQ:GRAL) Shares Gap DownHere's Why - MarketBeat
Are Multi-Cancer Blood Tests Ready for Prime Time? - WSJ
(GRAL) Risk Channels and Responsive Allocation - Stock Traders Daily
Archaeopteryx | The Holy Grail of Fossils at the Field Museum - Britannica
Finanzdaten der Grail Inc-Aktie (GRAL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.77%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):